Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ANIDULAFUNGIN GX; ANIDULAFUNGIN GA; ANIDULAFUNGIN ISL; ANIDULAFUNGIN JUNO; ANIDULAFUNGIN MEDIS; ANIDULAFUNGIN ZP (Medis Pharma Pty Ltd)
Product name
ANIDULAFUNGIN GX; ANIDULAFUNGIN GA; ANIDULAFUNGIN ISL; ANIDULAFUNGIN JUNO; ANIDULAFUNGIN MEDIS; ANIDULAFUNGIN ZP
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
127 (255 working days)
Active ingredients
anidulafungin
Registration type
New generic medicine
Indication
ANIDULAFUNGIN GX; ANIDULAFUNGIN GA; ANIDULAFUNGIN ISL; ANIDULAFUNGIN JUNO; ANIDULAFUNGIN MEDIS; ANIDULAFUNGIN ZP (powder for injection) is indicated as a treatment of invasive candidiasis, including candidaemia in adult and in paediatric patients one month and older (see Section 5.1 Pharmacodynamic Properties).
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine